Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS5580 and Palonosetron for Prevention of Postoperative Nausea and Vomiting
NCT07709897Phase 2Recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Aug 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 2 trial of fosrolapitant in postoperative nausea and vomiting (PONV), sponsored by Fujian Shengdi Pharmaceuticals. Started Aug 2026; status: recruiting.
02
Drugs
fosrolapitant
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT07709897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07709897.